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ABSTRACT: The International Liaison Committee on Resuscitation 
has initiated a continuous review of new, peer-reviewed, published 
cardiopulmonary resuscitation science. This is the second annual 
summary of International Consensus on Cardiopulmonary Resuscitation 
and Emergency Cardiovascular Care Science With Treatment 
Recommendations that includes the most recent cardiopulmonary 
resuscitation science reviewed by the International Liaison Committee 
on Resuscitation. This summary addresses the role of antiarrhythmic 
drugs in adults and children and includes the Advanced Life Support 
Task Force and Pediatric Task Force consensus statements, which 
summarize the most recent published evidence and an assessment of 
the quality of the evidence based on Grading of Recommendations, 
Assessment, Development, and Evaluation criteria. The statements 
include consensus treatment recommendations approved by members 
of the relevant task forces. Insights into the deliberations of each task 
force are provided in the Values and Preferences and Task Force Insights 
sections. Finally, the task force members have listed the top knowledge 
gaps for further research.
This is the second in a series of annual International Liaison Committee on Resuscitation (ILCOR) International Consensus on Cardiopulmonary Resusci-tation and Emergency Cardiovascular Care Science With Treatment Recom-
mendations (CoSTR) summary publications that summarize the ILCOR task force 
analyses of published resuscitation evidence. The review this year addresses the use 
of antiarrhythmic drugs for the management of adult and pediatric cardiac arrest 
and the period immediately after return of spontaneous circulation (ROSC). Draft 
CoSTRs were posted online on April 19, 2018,1 and included the data reviewed 
and draft treatment recommendations with comments accepted through May 15, 
2018. The draft Advanced Life Support (ALS) CoSTR was viewed by ≈4459 visitors 
(5 comments), and the Pediatric CoSTR was viewed by ≈1183 visitors (2 com-
ments). A total of 8 CoSTRs are now available online, and they have been viewed 
by ≈11 000 visitors.
This summary statement contains the final wording of the CoSTR as approved 
by the task forces and by the ILCOR member councils. This statement differs in 
several respects from the website draft CoSTRs: The language used to describe the 
evidence is not restricted to standard Grading of Recommendations, Assessment, 
Development, and Evaluation terminology, making it more transparent to a wider 
audience; the Values and Preferences and Task Force Insights sections have been 
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expanded to provide more transparency about the ra-
tionale for treatment recommendations; and finally, the 
task forces have prioritized knowledge gaps requiring 
future research studies.
The CoSTRs are based on task force analysis of the 
data and use the Grading of Recommendations, As-
sessment, Development, and Evaluation approach. 
This analysis is detailed in a systematic review pub-
lished by the Knowledge Synthesis Unit2 and the 
ILCOR topic experts. This Grading of Recommenda-
tions, Assessment, Development, and Evaluation ap-
proach rates the quality of evidence that supports the 
intervention effects (predefined by the PICO [popula-
tion, intervention, comparator, outcome] question) as 
high, moderate, low, or very low. Randomized con-
trolled trials (RCTs) begin the analysis as high-quality 
evidence, and observational studies begin the analysis 
as low-quality evidence. Five factors may lead to a 
downgrade of the quality of evidence, and 3 factors 
may enable an upgrade of the quality of the evidence 
(Tables 1 and 2). Each statement includes the perti-
nent outcome data listing both relative risk with 95% 
CI and risk difference (RD) with 95% CI. The RD is 
the absolute difference between the risks and is cal-
culated by subtracting the risk in the control group 
from the risk in the intervention group. This absolute 
effect enables a more clinically useful assessment of 
the magnitude of the effect of an intervention and 
enables calculation of the number needed to treat 
(number needed to treat=1/RD).
Outcome measures were ranked by the task forces 
by using an approach that is being applied consistently 
for all ILCOR PICO questions. Longer-term, patient-
centered outcomes are considered more important 
than process variables and shorter-term outcomes.3,4 In 
making these rankings, the task forces considered that 
shorter-term outcomes (eg, termination of ventricular 
fibrillation, ROSC, survival to hospital admission) are a 
useful measure of antiarrhythmic drug efficacy.
BACKGROUND
Antiarrhythmic drugs have a potential role in the treat-
ment of cardiac arrest with ventricular fibrillation (VF) 
or pulseless ventricular tachycardia (pVT) that is refrac-
tory to electric defibrillation attempts.5,6 This update on 
the role of antiarrhythmic drugs was prioritized by the 
ALS Task Force after publication of an RCT compar-
ing amiodarone, lidocaine, and placebo7 following the 
2015 ALS CoSTR.5,6 The Pediatric Task Force took the 
opportunity to rereview the most recent pediatric pub-
lished evidence.
Table 1. GRADE Terminology for Strength of Recommendation and 
Criteria for Evidence Quality Assessment
Strength of Recommendation
Strong Recommendation =  
We Recommend
Weak Recommendation =  
We Suggest
Evidence Quality Assessment Criteria
Study Design
Quality of 
Evidence Lower If Higher If
Randomized 
trial
High
Moderate
Risk of bias
Inconsistency
Indirectness 
Imprecision 
Publication bias
Large effect
Dose response
All plausible 
confounding 
would reduce 
demonstrated 
effect or would 
suggest a 
spurious effect 
when results 
show no effect
Observational 
study
Low 
Very low
GRADE indicates Grading of Recommendations, Assessment, Development, 
and Evaluation.
Table 2. GRADE Terminology
Risk of bias Study limitations in randomized trials include lack of 
allocation concealment, lack of blinding, incomplete 
accounting of patients and outcome events, selective 
outcome reporting bias, and stopping early for 
benefit. Study limitations in observational studies 
include failure to apply appropriate eligibility criteria, 
flawed measurement of exposure and outcome, 
failure to adequately control confounding, and 
incomplete follow-up.
Inconsistency Criteria for inconsistency in results include the 
following: Point estimates vary widely across studies; 
CIs show minimal or no overlap; statistical test for 
heterogeneity shows a low P value; and the I2 is large 
(a measure of variation in point estimates resulting 
from among-study differences).
Indirectness Sources of indirectness include data from studies 
with differences in population (eg, OHCA instead of 
IHCA, adults instead of children), differences in the 
intervention (eg, different CV ratios), differences in 
outcome, and indirect comparisons.
Imprecision Low event rates or small sample sizes will generally 
result in wide CIs and therefore imprecision.
Publication bias Several sources of publication bias include tendency 
not to publish negative studies and the influence of 
industry-sponsored studies. An asymmetrical funnel 
plot increases suspicion of publication bias.
Good practice 
statements
Guideline panels often consider it necessary to 
issue guidance on specific topics that do not lend 
themselves to a formal review of research evidence. 
The reason might be that research into the topic 
is unlikely to be located or would be considered 
unethical or infeasible. Criteria for issuing a 
nongraded good practice statement include the 
following: There is overwhelming certainty that 
the benefits of the recommended guidance will 
outweigh harms, and a specific rationale is provided; 
the statements should be clear and actionable to a 
specific target population; the guidance is deemed 
necessary and might be overlooked by some 
providers if not specifically communicated; and the 
recommendations should be readily implementable 
by the specific target audience to which the guidance 
is directed.
CV indicates compression-ventilation; GRADE, Grading of Recommendations, 
Assessment, Development, and Evaluation; IHCA, in-hospital cardiac arrest; and 
OHCA, out-of-hospital cardiac arrest.
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The reported incidence of adult VF/pVT cardiac ar-
rest varies according to the precise definitions used 
and the population studied. For treated adult out-of-
hospital cardiac arrest (OHCA), an initial arrest rhythm 
of VF/pVT was documented in 4.1% to 19.8% of ar-
rests in a series from 7 Asian countries,8 27.9% in a 
series from Australia and New Zealand,9 an average 
of 22.2% (range, 4.4%‒50%) in a series from 27 Eu-
ropean countries,10 and 21.3% in a report from the 
United States.11 There are far fewer international data 
for adult in-hospital cardiac arrest (IHCA), and the re-
ported incidence of initial VF/pVT is 18.9% in Italy,12 
16.9% in the United Kingdom,13 and 19.5% in the 
United States.14
An initial cardiac arrest rhythm of VF/pVT is less 
common in children than in adults, although the 
frequency varies greatly by age. In OHCA, an initial 
documented rhythm of VF/pVT has been reported 
in 3% to 14% of pediatric arrests in the All-Japan 
Utstein Registry,15–19 in 7% of pediatric arrests in Aus-
tralia,20 in 4% to 12% of pediatric arrests in Swe-
den,21 and in 6% to 7.8% of pediatric arrests in the 
United States.22–26 The frequency of VF/pVT as an 
initial arrest rhythm is typically lowest in children <5 
years of age, averaging 1% to 6%,15,18,19,21 and higher 
in adolescents, averaging 18% to 20% in Japan,15,18 
17% in Sweden,21 and 15% to 19.4% in the United 
States.22,23 Fewer data are available on the frequency 
of VF/pVT as the first reported arrest rhythm in pe-
diatric IHCA. An initial rhythm of VF/pVT has been 
reported in 9% of pediatric IHCA cases in Australia.27 
In the American Heart Association’s Get With The 
Guidelines–Resuscitation registry of IHCA events in 
3 pediatric cohorts with enrollment in overlapping 
years, 10% to 14% demonstrated an initial rhythm 
of VF/pVT.28–30 In a small multicenter/multicountry se-
ries of 40 IHCA events in 37 children who had a high 
incidence (56.8%) of cardiac disease and of previous 
cardiac arrests (24.3%), VF/pVT was the first assessed 
rhythm in 42.5% of events.31
Antiarrhythmic drugs are used to treat VF/pVT only 
if this rhythm persists after attempted defibrillation (ie, 
shock delivery). In a large RCT (n=23 711) of continuous 
or interrupted chest compressions during adult cardio-
pulmonary resuscitation (CPR) for OHCA,32 22.5% of 
patients had an initial rhythm of VF/pVT, and ≈6.7% 
of all patients received an antiarrhythmic drug (amio-
darone, 4.7%; lidocaine, 2%). In a large observational 
study (n=108 079) of airway management using data 
from the Get With The Guidelines–Resuscitation regis-
try of IHCA events, ≈18% of all patients had an initial 
rhythm of VF/pVT, and 25% of all patients received an 
antiarrhythmic drug (amiodarone, 17%; lidocaine, 8%) 
during attempted resuscitation.33
Reports of antiarrhythmic drug use during treat-
ment of pediatric cardiac arrest are extremely limited. 
Two cohort series published from the Get With The 
Guidelines–Resuscitation registry of IHCA events en-
rolled patients in overlapping years. In the first study 
of 1005 consecutive pediatric patients enrolled from 
2000 to 2004, 10% had initial VF/pVT and 27% had 
VF/pVT at some time during the arrest. A total of 
24% of all patients received an antiarrhythmic drug. 
Amiodarone was administered to 23% and lidocaine 
to 47% of those patients with VF/pVT.29 Another 
larger series from the same registry enrolled 553 
children with VF/pVT from 2000 to 2005. Nearly half 
(49%) of those who had VF/pVT were treated with 
an antiarrhythmic drug; 19.5% of those with VF/pVT 
received amiodarone. Approximately two-thirds of 
the children who received amiodarone also received 
lidocaine.34
In the following sections, we include the predefined 
PICO question addressed by the systematic review; the 
summary CoSTR; the values, preferences, and insights 
of the task force during the consensus process; and 
the priority knowledge gaps. The summary CoSTR for 
adults is described first, followed by that for children 
and infants.
THE POPULATION, INTERVENTION, 
COMPARATOR, OUTCOME, STUDY 
DESIGNS, AND TIME FRAME
Population
Adults and children in any setting (in hospital or out 
of hospital) with cardiac arrest and a shockable rhythm 
(VF/pVT) at any time during CPR or immediately after 
ROSC were included.
Intervention
Intervention included administration (intravenous or 
intraosseous) of an antiarrhythmic drug during CPR or 
immediately (within 1 hour) after ROSC.
Comparators
Comparators included another antiarrhythmic drug or 
placebo or no drug during CPR or immediately (within 
1 hour) after ROSC.
Outcomes
Survival to hospital discharge with good neurological 
outcome and survival to hospital discharge were ranked 
as critical outcomes. ROSC was ranked as an impor-
tant outcome. For an antiarrhythmic drug given within 
1 hour of ROSC, rearrest was included as an important 
outcome.
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Study Designs
RCTs and nonrandomized studies (non-RCTs, inter-
rupted time series, controlled before-and-after studies, 
cohort studies) were eligible for inclusion.
Time Frame
All years and all languages were included as long as 
there was an English abstract; unpublished studies (eg, 
conference abstracts, trial protocols) were excluded.
The literature search was updated to August 
15, 2017. A search of the MEDLINE, Embase, and 
Cochrane Library identified 9371 records after removal 
of duplicates. After the records were screened, 409 full-
text articles were assessed for eligibility. Fourteen adult 
RCTs (16 articles) and 19 non-RCTS (18 adult studies, 1 
pediatric study, 22 articles) were considered by the task 
forces to develop the CoSTR.
USE OF ANTIARRHYTHMIC DRUGS 
DURING RESUSCITATION OF ADULTS 
WITH VF/pVT CARDIAC ARREST OR 
IMMEDIATELY AFTER ROSC
Consensus on Science
The systematic review included searches to identify 
comparative data on the use of antiarrhythmic drugs, 
including amiodarone versus placebo, lidocaine versus 
placebo, amiodarone versus lidocaine, magnesium ver-
sus placebo, bretylium versus placebo, lidocaine versus 
bretylium, amiodarone versus nifekalant, lidocaine ver-
sus nifekalant, and lidocaine versus sotalol. Given the 
availability of comparative data from RCTs, the ALS Task 
Force did not focus on the data from non-RCTs when 
evaluating the estimated effect size of these drugs and 
included only data from the RCTs in the meta-analyses 
in this document. The reason is that the 18 adult obser-
vational studies identified had substantial heterogene-
ity and unmeasured confounders, including “resuscita-
tion time bias.”35
The amiodarone versus placebo comparison is based 
on 2 RCTs: the ARREST trial (Amiodarone in the Out-of-
Hospital Resuscitation of Refractory Sustained Ventricu-
lar Tachyarrhythmias)36 and the ROC-ALPS trial (Resus-
citation Outcomes Consortium Amiodarone, Lidocaine, 
or Placebo Study).7 The amiodarone versus lidocaine 
comparison is based on 2 RCTs: the ALIVE trial (Amio-
darone Versus Lidocaine in Prehospital Ventricular Fibril-
lation Evaluation)37 and the ROC-ALPS trial.7 For results 
of these trials, we have provided pooled estimates and 
individual study estimates (the reasons are described 
later in the Values and Preferences and ALS Task Force 
Insights section). No RCTs were identified that addressed 
the use of antiarrhythmic drugs immediately after ROSC 
(defined as within 1 hour after ROSC). The summary of 
findings and point estimates are shown in Table 3.
Table 3. Summary of Findings: Antiarrhythmic Drugs for Adult Cardiac Arrest With Refractory VF/pVT
Outcomes (Importance)
Participants 
(Studies), n
Certainty of the 
Evidence (GRADE) RR (95% CI)
Anticipated Absolute Effects, n
Risk With 
Standard Care
RD With Intervention+ 
Standard Care
Amiodarone vs placebo
  Survival to hospital discharge with 
good neurological outcome (combined) 
(Critical)
2526 (2 RCTs)7,36 Very low 1.13 (0.95‒1.36) 146 per 1000 19 more per 1000 (from 7 
fewer to 53 more)
  Survival to hospital discharge with good 
neurological outcome (Cordarone) 
(Critical)
504 (1 RCT)36 Very low 1.11 (0.59‒2.10) 66 per 1000 7 more per 1000 (from 27 
fewer to 72 more)
  Survival to hospital discharge with 
good neurological outcome (Nexterone) 
(Critical)
2022 (1 RCT)7 Moderate 1.13 (0.94‒1.37) 166 per 1000 22 more per 1000 (from 10 
fewer to 61 more)
  Survival to hospital discharge 
(combined) (Critical)
2530 (2 RCTs)7,36 Very low 1.14 (0.98‒1.33) 195 per 1000 27 more per 1000 (from 4 
fewer to 64 more)
  Survival to hospital discharge 
(Cordarone) (Critical)
504 (1 RCT)36 Very low 1.02 (0.65‒1.59) 132 per 1000 3 more per 1000 (46 fewer 
to 78 more)
  Survival to hospital discharge 
(Nexterone) (Critical)
2026 (1 RCT)7 Moderate 1.16 (0.99‒1.37) 210 per 1000 34 more per 1000 (2 fewer 
to 78 more)
  ROSC (combined) (Important) 2537 (2 RCTs)7,36 Very low 1.13 (0.93‒1.37) 345 per 1000 45 more per 1000 (from 24 
fewer to 128 more)
  ROSC (Cordarone) (Important) 504 (1 RCT)36 Very low 1.27 (1.02‒1.59) 345 per 1000 93 more per 1000 (from 7 
more to 204 more)
  ROSC (Nexterone) (Important) 2033 (1 RCT)7 Moderate 1.04 (0.92‒1.17) 346 per 1000 14 more per 1000 (from 28 
fewer to 59 more)
(Continued )
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Lidocaine vs placebo
  Survival to hospital discharge with good 
neurological outcome (Critical)
2039 (1 RCT)7 Moderate 1.05 (0.87‒1.28) 166 per 1000 8 more per 1000 (from 22 
fewer to 46 more)
  Survival to hospital discharge (Critical) 2041 (1 RCT)7 Moderate 1.13 (0.96‒1.32) 210 per 1000 27 more per 1000 (from 8 
fewer to 67 more)
  ROSC (Important) 2051 (1 RCT)7 High 1.16 (1.03‒1.29) 346 per 1000 55 more per 1000 (from 10 
more to 100 more)
Amiodarone vs lidocaine
  Survival to hospital discharge with good 
neurological outcome (Critical)
1951 (1 RCT)7 Moderate 1.08 (0.89‒1.30) 175 per 1000 14 more per 1000 (from 19 
fewer to 52 more
  Survival to hospital discharge 
(combined) (Critical)
2302 (2 RCTs)7,37 Very low 1.04 (0.89‒1.22) 207 per 1000 8 more per 1000 (from 23 
fewer to 45 more)
  Survival to hospital discharge (lidocaine 
with polysorbate 80) (Critical)
347 (1 RCT)37 Very low 1.67 (0.57‒4.88) 30 per 1000 20 more per 1000 (from 13 
fewer to 116 more)
  Survival to hospital discharge (Critical) 1955 (1 RCT)7 Moderate 1.03 (0.88‒1.21) 237 per 1000 7 more per 1000 (from 28 
fewer to 50 more)
  ROSC (Important) 1966 (1 RCT)7 Moderate 0.90 (0.80‒1.01) 399 per 1000 40 fewer per 1000 (from 
80 fewer to 4 more)
Magnesium vs placebo
  Survival to hospital discharge with good 
neurological outcome (Critical)
332 (3 RCTs)38–40 Very low 2.08 (0.87‒4.97) 35 per 1000 38 more per 1000 (from 5 
fewer to 140 more)
  Survival to hospital discharge (Critical) 437 (4 RCTs)38–41 Very low 1.07 (0.62‒1.86) 90 per 1000 6 more per 1000 (from 34 
fewer to 77 more)
  ROSC (Important) 437 (4 RCTs)38–41 Very low 0.97 (0.77‒1.24) 327 per 1000 4 more per 1000 (from 83 
less to 92 more)
Bretylium vs placebo
  Survival to hospital discharge (Critical) 29 (1 RCT)42 Very low 4.28 (0.60‒30.26) 91 per 1000 298 more per 1000 (from 
43 fewer to 535 more)
Lidocaine vs bretylium
  Survival to hospital discharge (Critical) 237 (2 RCTs)43,44 Very low 0.84 (0.51‒1.36) 235 per 1000 38 fewer per 1000 (from 
143 fewer to 66 more)
  ROSC (Important) 237 (2 RCTs)43,44 Very low 1.23 (0.78‒1.92) 496 per 1000 114 more per 1000 (from 
109 fewer to 456 more)
Amiodarone vs nifekalant
  Survival to hospital discharge with good 
neurological outcome (Critical)
30 (1 RCT)45 Very low 1.00 (0.31‒3.28) 267 per 1000 0 more per 1000 (from 184 
fewer to 608 more)
  Survival to hospital discharge (Critical) 30 (1 RCT)45 Very low 2.00 (0.76‒5.24) 267 per 1000 267 more per 1000 (from 
77 fewer to 536 more)
  ROSC (Important) 30 (1 RCT)45 Very low 1.43 (0.75‒2.73) 467 per 1000 201 more per 1000 (from 
117 fewer to 807 more)
Lidocaine vs nifekalant
  Survival to hospital discharge (Critical) 28 (1 RCT)46 Very low … 0 per 1000 0 more per 1000
  ROSC (Important) 22 (1 RCT)46 Very low 0.23 (0.06‒0.92) 625 per 1000 481 fewer per 1000 (from 
587 fewer to 50 fewer)
Lidocaine vs sotalol
  Survival to hospital discharge with good 
neurological outcome (Critical)
129 (1 RCT)47 Low 6.10 (0.32‒115.76) 0 per 1000 43 more per 1000 (from 23 
fewer to 120 more)
  Survival to hospital discharge (Critical) 129 (1 RCT)47 Low 2.17 (0.44‒10.80) 33 per 1000 39 more per 1000 (from 19 
fewer to 327 more)
  ROSC (Important) 129 (1 RCT)47 Low 1.41 (0.84‒2.37) 267 per 1000 109 more per 1000 (from 
43 fewer to 365 more)
GRADE indicates Grading of Recommendations, Assessment, Development, and Evaluation; RCT, randomized controlled trial; RD, risk difference; ROSC, return 
of spontaneous circulation; RR, relative risk; and VF/pVT, ventricular fibrillation/pulseless ventricular tachycardia.
Table 3. Continued
Outcomes (Importance)
Participants 
(Studies), n
Certainty of the 
Evidence (GRADE) RR (95% CI)
Anticipated Absolute Effects, n
Risk With 
Standard Care
RD With Intervention+ 
Standard Care
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Amiodarone Versus Placebo
The combined evidence from 2 RCTs (the ARREST and 
ROC-ALPS trials) comparing amiodarone with placebo 
for OHCA showed, with very low certainty, no statisti-
cally significant difference in survival to hospital dis-
charge with good neurological outcome (n=2526), 
survival to hospital discharge (n=2530), or ROSC 
(n=2537).7,36 The quality of this combined evidence 
was downgraded because of concerns about risk of 
bias, indirectness, and imprecision. The ARREST trial36 
risk of bias was noted because investigators did not 
report intention-to-treat data. Although the ROC-ALPS 
trial enrolled patients from 2013 to 2015, the risk of 
indirectness was noted because resuscitation practice 
at the time of the patient enrollment for the ARREST 
trial (1994‒1997) differed substantially from current 
practice. An additional risk of indirectness resulted 
from the fact that the placebo groups in both trials 
received polysorbate 80. Concerns about differences 
in resuscitation practice at the time of patient enroll-
ment and about the use of the polysorbate 80 placebo 
are discussed further in the Values and Preferences and 
ALS Task Force Insights section of this article. The wide 
CIs around the point estimates, the number of events, 
and a sample size that did not meet the optimal infor-
mation size criteria resulted in a downgrade for impre-
cision; this raises concerns that both studies may have 
been underpowered to detect a clinically meaningful 
treatment effect.48
One RCT, the ARREST trial, involved 504 patients 
and compared the Cordarone (amiodarone in poly-
sorbate 80) preparation of amiodarone with an active 
polysorbate 80 placebo.36 This study showed, with very 
low certainty, no statistically significant difference in 
survival to hospital discharge with good neurological 
outcome or survival to hospital discharge. However, it 
did show a statistically significant increase in ROSC. For 
the same reasons given for the combined data stated 
earlier, the quality of this evidence was downgraded 
because of concerns about risk of bias, indirectness, 
and imprecision.
One RCT, the ROC-ALPS trial, compared the Nex-
terone preparation of amiodarone with saline placebo. 
This trial showed, with moderate certainty, no statistical-
ly significant difference in survival to hospital discharge 
with good neurological outcome (n=2022), survival to 
hospital discharge (n=2026), or ROSC (n=2033).7 The 
quality of the evidence was downgraded because of 
concerns about imprecision that related to wide CIs 
around the point estimates, the number of events, and 
a sample size that did not meet the optimal information 
size criteria.
Lidocaine Versus Placebo
One RCT, the ROC-ALPS trial, compared lidocaine with 
placebo.7 This study showed, with moderate certain-
ty, no statistically significant difference in survival to 
hospital discharge with good neurological outcome 
(n=2039) or survival to hospital discharge (n=2041). 
The quality of the evidence was downgraded because 
of concerns about imprecision related to wide CIs 
around the point estimates, the number of events, 
and a sample size that did not meet the optimal infor-
mation size criteria.
The same RCT (ROC-ALPS) compared lidocaine with 
placebo and involved 2051 patients. This trial showed, 
with high certainty, a statistically significant increase in 
ROSC favoring lidocaine.7
Amiodarone Versus Lidocaine
One RCT (ROC-ALPS) compared amiodarone with li-
docaine and showed, with moderate certainty, no 
statistically significant difference in survival to hospital 
discharge with good neurological outcome (n=1951), 
survival to hospital discharge (n=1955), or ROSC 
(n=1966).7 The quality of the evidence was downgrad-
ed because of concerns about imprecision that related 
to wide CIs around the point estimates, the number of 
events, and a sample size that did not meet the optimal 
information size criteria.
Two RCTs, the ALIVE trial37 and the ROC-ALPS tri-
al,7 compared amiodarone with lidocaine and involved 
2302 patients. These trials showed, with very low cer-
tainty, no statistically significant difference in survival to 
hospital discharge.7,37 The quality of this combined evi-
dence was downgraded because of concerns about risk 
of indirectness and imprecision. The ALIVE trial37 was at 
risk of indirectness because resuscitation practice at the 
time of patient enrollment (1995‒2001) differed sub-
stantially from current practice. In addition, lidocaine 
was mixed with polysorbate 80, a preparation that is 
not used commercially; the effects of adding polysor-
bate 80 to the lidocaine are uncertain. The wide CIs 
around the point estimates, the number of events, and 
a sample size that did not meet the optimal information 
size criteria resulted in a downgrade for imprecision.
One RCT (the ALIVE trial) compared amiodarone 
with lidocaine mixed with polysorbate 80 and involved 
347 patients. This trial showed, with very low certainty, 
no statistically significant difference in survival to hospi-
tal discharge.37 The quality of this evidence was down-
graded because of concerns about indirectness and 
imprecision for the reasons given previously.
Magnesium Versus Placebo
Three RCTs comparing magnesium with placebo and 
involving 332 patients showed, with very low certainty, 
no statistically significant difference in survival to hospi-
tal discharge with good neurological outcome.38–40 The 
quality of this evidence was downgraded because of risk 
of bias, imprecision, and indirectness. The risk of bias 
resulted from uncertainties about allocation conceal-
ment and blinding of clinicians and outcome assessors. 
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The wide CIs around the point estimates, the number of 
events, and a sample size that did not meet the optimal 
information size criteria resulted in the downgrade for 
imprecision. The risk of indirectness was noted because 
resuscitation practice at the times of patient enrollment 
(all 3 studies completed enrollment before the publica-
tion of the 2000 International Consensus recommenda-
tions and 2000 council guidelines) differed substantially 
from current practice, and 2 of these studies39,40 included 
patients who had arrest rhythms other than VF/pVT.
Four RCTs (the 3 studies cited in the previous para-
graph38–40 plus an additional study41) compared mag-
nesium with placebo and involved 437 patients. These 
studies showed, with very low certainty, no statistically 
significant difference in survival to hospital discharge or 
ROSC.38–41 The quality of this evidence was downgraded 
because of concerns about risk of bias and imprecision 
for reasons given previously. In all 4 studies, patients 
were treated according to pre-2000 resuscitation guide-
lines, which differ considerably from current practice. As 
a result, all 4 studies were downgraded for indirectness.
Bretylium Versus Placebo
One RCT comparing bretylium with placebo in 29 pa-
tients showed, with very low certainty, no statistically 
significant difference in survival to hospital discharge.42 
The quality of this evidence was downgraded because 
of concerns about risk of bias, indirectness, and im-
precision. The risk of bias resulted from uncertainties 
about sequence generation, allocation concealment, 
and blinding of participants. The risk of indirectness 
was noted because resuscitation practice at the time of 
patient enrollment (well before 2000) differed substan-
tially from current practice. The wide CIs around the 
point estimates, the number of events, and a sample 
size that did not meet the optimal information size cri-
teria resulted in the downgrade for imprecision.
Lidocaine Versus Bretylium
Two RCTs comparing lidocaine with bretylium in 237 
patients showed, with very low certainty, no statistically 
significant difference in survival to hospital discharge or 
ROSC.43,44 The quality of this evidence was downgraded 
because of concerns about risk of bias, indirectness, and 
imprecision. The risk of bias resulted from uncertainties 
about sequence generation, allocation concealment, 
and blinding of participants. The risk of indirectness was 
present because resuscitation practice at the time of pa-
tient enrollment for both studies (well before 2000) dif-
fered substantially from current practice. The wide CIs 
around the point estimates, the number of events, and 
a sample size that did not meet the optimal information 
size criteria resulted in the downgrade for imprecision.
Amiodarone Versus Nifekalant
One controlled trial comparing amiodarone with nifeka-
lant in 30 patients (enrolled 2007‒2009) showed, with 
very low certainty, no statistically significant difference 
in survival to hospital discharge with good neurological 
outcome, survival to hospital discharge, or ROSC.45 The 
quality of this evidence was downgraded because of con-
cerns about risk of bias and imprecision. The risk of bias 
resulted from concerns about sequence generation and 
allocation concealment and uncertainties about blind-
ing of participants and outcome assessors. The wide CIs 
around the point estimates, the number of events, and 
a sample size that did not meet the optimal information 
size criteria resulted in the downgrade for imprecision.
Lidocaine Versus Nifekalant
One controlled trial comparing lidocaine with nifeka-
lant showed, with very low certainty, no statistically 
significant difference in survival to hospital discharge 
(n=28) or ROSC (n=22).46 The quality of this evidence 
was downgraded because of concerns about risk of 
bias, imprecision, and indirectness. The risk of bias re-
sulted from concerns about sequence generation and 
allocation concealment, uncertainties about blinding 
of participants and outcome assessors, and incomplete 
reporting of outcomes. The imprecision resulted from 
the fact that the sample size for survival to hospital dis-
charge did not meet the optimal information size cri-
teria, and the effect estimate could not be determined 
because there were no survivors in either arm. For the 
outcome of ROSC, the CIs around the point estimates 
were wide, and the sample size was too small. The 
study was downgraded for indirectness because at the 
time of study enrollment (2001‒2004), resuscitation 
practice differed substantially from current practice.
Lidocaine Versus Sotalol
One controlled trial comparing lidocaine with sotalol 
showed, with low certainty, no statistically significant 
difference in survival to hospital discharge with good 
neurological outcome (n=129), survival to hospital 
discharge (n=129), or ROSC (n=129).47 The quality of 
this evidence was downgraded as a result of concerns 
about imprecision because the CIs around the point es-
timates were wide, because of the number of events, 
and because the sample size did not meet the optimal 
information size criteria. The study was downgraded 
for indirectness because the study enrolled patients be-
fore publication of the 2005 ILCOR CoSTR and council 
guidelines recommendations that resulted in substan-
tial alterations in resuscitation practice.
Treatment Recommendations
We suggest the use of amiodarone or lidocaine in adults 
with shock-refractory VF/pVT (weak recommendation, 
low-quality evidence).
We suggest against the routine use of magnesium in 
adults with shock-refractory VF/pVT (weak recommen-
dation, very low-quality evidence).
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The confidence in effect estimates is currently too 
low to support an ALS Task Force recommendation 
about the use of bretylium, nifekalant, or sotalol in 
the treatment of adults in cardiac arrest with shock-
refractory VF/pVT.
The confidence in effect estimates is currently too low 
to support an ALS Task Force recommendation about the 
use of prophylactic antiarrhythmic drugs immediately 
after ROSC in adults with VF/pVT cardiac arrest.
Values and Preferences and ALS Task 
Force Insights
In making these recommendations, the ALS Task Force 
considered the following.
Amiodarone or Lidocaine
We considered the predefined and reported bystander-
witnessed arrest subgroup (n=1934) analysis of the 
ROC-ALPS study7 that showed a significant improve-
ment with an antiarrhythmic drug for the critical out-
come of survival to hospital discharge. Specifically, 
survival was higher with amiodarone (27.7%) or lido-
caine (27.8%) than with placebo (22.7%). This abso-
lute RD was significant for amiodarone (5.0%; 95% 
CI, 0.3‒9.7; P=0.04) or lidocaine (RD, 5.2%; 95% CI, 
0.5‒9.9; P=0.03) compared with placebo but not for 
amiodarone compared with lidocaine (RD, −0.1%; 
95% CI, −5.1 to 4.9; P=0.97).
The survival to hospital discharge in the ROC-ALPS 
trial was also higher among amiodarone recipients than 
placebo recipients in the emergency medical services‒ 
witnessed arrest subgroup (n=154).7 Survival was 
higher with amiodarone (38.6%) than with placebo 
(16.7%). This was associated with earlier drug use: The 
time from cardiac arrest to the first dose of trial drug 
was 11.7±5.8 minutes for those with emergency medi-
cal services–witnessed arrest versus a time from 9-1-1 
call to the first study drug of 19.3±7.1 minutes for 
those with non‒emergency medical services–witnessed 
cardiac arrest.
We did not identify any RCTs comparing outcomes 
of amiodarone or lidocaine for IHCA. We acknowledge 
that drug delivery during resuscitation is typically much 
earlier in the inpatient setting,49,50 raising the possibility 
that these drugs may be beneficial for the IHCA popula-
tion. However, we also acknowledge that there is a lack 
of RCT data for IHCA.
In making a weak recommendation, we considered 
the reported small increase in the short-term outcome 
of ROSC in those treated with amiodarone in the 1999 
ARREST study36 and in those treated with lidocaine in 
the 2016 ROC-ALPS study.7 Neither drug was associ-
ated with a difference in the longer-term outcomes that 
were ranked as critical: survival or good neurological 
survival to hospital discharge. The systematic review 
identified no data on the outcomes of health-related 
quality of life or burdens and costs of treatment.
The ALS Task Force recognizes that the selected val-
ues for outcomes (we ranked ROSC as an important 
outcome) may not be the same as those that patients 
and families would choose. It is possible that patients 
who will not survive to hospital discharge and their 
families may value patient ROSC because it may provide 
family members with some preparation time before a 
final declaration of death. This is a knowledge gap. Pa-
tients, families, and society may also place a value on 
ROSC that is based on the possibility of organ donation 
and the continued support needed to enable organ do-
nation. The task force also recognizes that ROSC may 
lead to an increased burden on healthcare systems if 
patients do not survive to hospital discharge.
In ROC-ALPS,7 there was no difference between 
amiodarone and lidocaine in survival or good neuro-
logical outcome at hospital discharge, and the task 
force made the same weak recommendation for both 
amiodarone and lidocaine. In the 2015 CoSTR,5,6 the 
quality of the evidence favoring amiodarone was rated 
as moderate, whereas the quality of the evidence for 
lidocaine was rated as very low.
Given the high-quality evidence for improved ROSC 
with lidocaine from the ROC-ALPS,7 the task force 
considered giving a stronger recommendation for li-
docaine than amiodarone. However, the lack of differ-
ence for critical outcomes (survival and survival with 
favorable neurological outcome on hospital discharge) 
between the drugs led the task force to assign the 
same level of recommendation and quality of evidence 
for both drugs.
We considered the differences between the 2 RCTs 
with amiodarone versus placebo (ie, the ARREST trial36 
and the ROC-ALPS trial7) and the 2 RCTs with amioda-
rone versus lidocaine (ie, the ALIVE trial37 and the ROC-
ALPS trial7). We discussed the benefits of pooling data 
versus keeping the studies separate in the systematic 
review and meta-analyses. The benefits of increasing 
precision of an estimate of effect were weighed against 
the detrimental effects of combining distinctly differ-
ent studies. We have provided pooled estimates based 
on combining studies and analyzed those from the in-
dividual studies. The following issues with the ARREST 
study36 and ROC-ALPS7 trial were considered for the 
amiodarone versus placebo comparison:
1. The ARREST study included patients with VF/pVT 
at any stage in the resuscitation attempt who had 
received 3 shocks. In comparison, the ROC-ALPS 
study included only those with an initial arrest 
rhythm of VF/pVT who had received at least 1 
shock. The actual number of shocks given before 
the trial drug in the ARREST study was a mean of 
5 (SD, ±2; median, 4) and in the ROC-ALPS study 
was a median of 3 (interquartile range, 2‒4).
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2. The ARREST study used an amiodarone in poly-
sorbate 80 preparation and compared it with a 
polysorbate 80 placebo. The potential effects of 
polysorbate 80 are debated: It may have hemody-
namic effects (possible transient hypotension), so 
there is a possibility that the control was harmed 
by an active placebo. The task force did not iden-
tify any human or animal studies comparing the 
effects of polysorbate 80 with 0.9% sodium chlo-
ride during CPR for shock-refractory VF/pVT. The 
effect of polysorbate 80 on the outcomes of the 
ARREST study is therefore unknown.
3. The ROC-ALPS trial used the Nexterone formula-
tion of amiodarone and an inactive placebo (0.9% 
sodium chloride). Nexterone is a newer formula-
tion of amiodarone that uses the diluent Captisol 
(a sulfobutyl ether β-cyclodextrin) instead of poly-
sorbate 80.
4. There were considerable changes in the manage-
ment of refractory VF/pVT between the time of 
patient enrollment in the ARREST trial (1994‒1997) 
and the time of patient enrollment in the ROC-ALPS 
trial (2013‒2015). Many of the practices used in 
the ARREST study (published in 1999 with patients 
enrolled 1994‒1997) were consistent with recom-
mendations in the 1992 American Heart Association 
“Guidelines for Cardiopulmonary Resuscitation 
and Emergency Cardiac Care,”51 including initial 
delivery of 2 slow rescue breaths and a pause for 
pulse check before initiation of chest compres-
sions, recommended compression depth of 1.5 to 
2 in (4‒5 cm) at rate of 80 to 100 per minute, use 
of a compression-ventilation ratio of 15:2, use of 
monophasic defibrillators to deliver up to 3 stacked 
shocks without intervening compressions, use of 
escalating energy levels, and pauses in compres-
sions during charging before shock delivery. By 
the time patients were enrolled in the ROC-ALPS 
trial, ILCOR recommendations and council guide-
lines had been revised in 2005 and again in 2010, 
replacing the 1992 recommendations with new 
approaches such as delivery of 1 shock followed by 
immediate CPR, compression rate of at least 100 
per minute, and other approaches designed to 
minimize interruptions in chest compressions as 
part of the delivery of high-quality CPR.
5. We are unable to ascertain the intention-to-treat 
population for the ARREST study and thus can 
compare only the per-protocol analysis.
The following issues with the ALIVE study37 were 
considered for the amiodarone versus lidocaine com-
parison:
1. Many of the practices used to manage patients in 
the ALIVE study (study published in 2002, patients 
enrolled 1995‒2001) have been superseded, as 
noted previously.
2. The ALIVE study included patients with initial VF/
pVT who received 3 shocks, adrenaline, and a fourth 
shock, whereas the ROC-ALPS trial included those 
with an initial arrest rhythm of VF/pVT who received 
at least 1 shock. The actual number of shocks given 
before the trial drug in the ALIVE study was a mean 
of 5 (SD, ±2; median, 4) and in the ROC-ALPS trial 
was a median of 3 (interquartile range, 2‒4).
3. In the ALIVE study, lidocaine was mixed with poly-
sorbate 80 (the diluent for amiodarone) to improve 
blinding because polysorbate 80 is viscous. It is 
unknown whether the addition of polysorbate 80 
(with potential hemodynamic effects) to lidocaine 
adversely affected outcomes in the lidocaine group.
We note that the reported risk of harm associated with 
amiodarone or lidocaine use during cardiac arrest was 
small. Specifically, the ROC-ALPS trial7 reported a small 
increase in the need for temporary pacing in the first 
24 hours after ROSC in the amiodarone group com-
pared with the lidocaine and placebo groups (4.9% ver-
sus 3.2% versus 2.7%) in the per-protocol population 
(P=0.02). There was, however, no difference among pa-
tients who received amiodarone, lidocaine, or placebo 
in the percent of patients with a poor neurological out-
come (modified Rankin Scale score 4 or 5) at hospital dis-
charge (5.4% for amiodarone versus 6.1% for lidocaine 
versus 4.3% for placebo) in the per-protocol population.
Magnesium
We did not identify any RCTs published since the 
2015 CoSTR5,6 that evaluated the role of magnesium 
in the treatment of VF/pVT. The 4 RCTs evaluated in 
the 2015 CoSTR reported the outcomes of a total of 
437 patients,38–41 with the most recent study published 
in 2002, which noted that the enrolled patients were 
treated in a manner consistent with the 1992 Euro-
pean resuscitation guidelines.52 Two of these studies 
included patients who had arrest rhythms other than 
VF/pVT.39,40 In making a suggestion against the routine 
use of magnesium for refractory VF/pVT cardiac arrest, 
we recognize that there are specific circumstances in 
which magnesium could be considered during refractory 
VF/pVT (eg, hypomagnesemia, torsades de pointes).
Bretylium, Nifekalant, and Sotalol
In making no recommendation about the use of brety-
lium, nifekalant, or sotalol, we considered guidance from 
the Grading of Recommendations, Assessment, Devel-
opment, and Evaluation handbook.53 We recognize that 
bretylium is not available in most settings for clinical use 
and is not part of current council guidelines internation-
ally. We did not identify any RCTs that compared nifeka-
lant with a placebo. We identified only the single very 
small RCT with 30 patients that compared amiodarone 
with nifekalant45 and another very small RCT with 28 pa-
tients that compared lidocaine with nifekalant.46 Sotalol 
is not part of current council guidelines internationally.
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The role of β-blocker drugs during and after cardiac 
arrest remains a knowledge gap. The ILCOR member 
resuscitation councils can best determine whether to 
recommend any change in current practice concerning 
these drugs.
Prophylactic Use of Antiarrhythmic Drugs 
Immediately After ROSC
We did not identify any RCTs for the prophylactic use of 
antiarrhythmic drugs in patients during the first hour af-
ter ROSC following a VF/pVT cardiac arrest, and we have 
identified this as a knowledge gap. No recommendation 
was made for or against prophylactic antiarrhythmic 
drugs after ROSC in the 2015 CoSTR,5,6 after analysis of 
2 observational studies,54,55 and we have not identified 
any additional evidence to support a recommendation.
Additional Peer-Reviewed Evidence  
and Additional ALS Task Force Insights
We identified 1 additional RCT that met our inclusion 
criteria.56 This RCT of subjects experiencing OHCA 
compared amiodarone, lidocaine, and saline placebo 
for patients with an initial nonshockable rhythm that 
later transitioned to a shockable rhythm. This study was 
underpowered for the primary end point of survival to 
hospital discharge.
Finally, the ALS Task Force recognizes that all the cur-
rently available RCTs are underpowered to detect any 
small effect sizes of antiarrhythmic drugs that could 
lead to many more survivors. For example, a 1% ab-
solute increase in survival from OHCA with an antiar-
rhythmic drug could lead to ≈600 additional survivors 
in North America each year.7 To detect these small dif-
ferences for critical outcomes (survival to discharge and 
good neurological survival) requires very large RCTs 
(tens of thousands of patients), and these may not be 
feasible. In the absence of large RCTs, combining data 
by using approaches such as network meta-analyses 
and sensitivity analyses of the meta-analyses and by us-
ing data from large observational studies or large regis-
tries in addition to RCTs could potentially overcome the 
shortcomings (inadequately powered RCTs, study qual-
ity, changes in resuscitation technique over time) in the 
evidence reviewed for this CoSTR.
ALS Task Force Knowledge Gaps
Current knowledge gaps for the use of antiarrhythmic 
drugs in adult refractory VF/pVT include but are not lim-
ited to the following:
• For VF/pVT cardiac arrest, do antiarrhythmic drugs 
improve patient-centered outcomes (survival with 
good neurological outcome, health-related quality 
of life), and do the outcomes differ within or across 
specific populations (OHCA or IHCA) or conditions 
(eg, witnessed arrest, monitored arrest, bystander 
CPR, number of shocks, CPR quality)?
• Does the use of epinephrine (adrenaline) affect the 
effectiveness of antiarrhythmic drugs during CPR 
for VF/pVT cardiac arrest and, if so, how?
• Is the use of multiple antiarrhythmic drugs (eg, 
amiodarone followed by lidocaine) more effec-
tive than the use of a single drug during CPR for 
VF/pVT cardiac arrest?
• Is there a difference in effectiveness between 
intravenous and intraosseous antiarrhythmic drug 
administration during CPR for VF/pVT cardiac 
arrest, and does the intraosseous site (humeral, 
tibial, other) make a difference?
• Does nifekalant improve critical outcomes com-
pared with placebo or alternative antiarrhythmic 
drugs during CPR for VF/pVT cardiac arrest?
• Does treatment with prophylactic antiarrhythmic 
drugs (including β-blockers) given immediately 
after ROSC improve outcome following VF/pVT 
cardiac arrest?
USE OF ANTIARRHYTHMIC DRUGS IN 
INFANTS AND CHILDREN WITH VF/pVT 
CARDIAC ARREST
Consensus on Science
Previous CoSTR statements evaluating the use of antiar-
rhythmic drugs during pediatric VF/pVT cardiac arrest, 
including the 2015 ILCOR Pediatric CoSTR,57,58 have in-
cluded extrapolated evidence from adult OHCA studies 
and case series of children with life-threatening ven-
tricular arrhythmias but not cardiac arrest. The ILCOR 
Pediatric Task Force concluded the 2015 review with 
a weak recommendation suggesting that amiodarone 
or lidocaine may be used for the treatment of pediat-
ric shock-resistant VF/pVT (weak recommendation, very 
low-quality evidence).57,58
The Pediatric Task Force agreed that this 2018 ILCOR 
CoSTR would not review evidence extrapolated from 
studies of adult cardiac arrest. Any such extrapolation 
would result in very low-quality evidence as a conse-
quence of indirectness because, regardless of location, 
the causes and presentation of children in cardiac arrest 
differ substantially from the causes and presentation of 
adults in cardiac arrest. When the initial pediatric cardiac 
arrest rhythm is VF/pVT, the infant or child often has con-
genital heart disease, inherited arrhythmia syndromes, 
commotio cordis, or cardiomyopathies that can influ-
ence presentation, treatment, and response to therapy. 
Subsequent VF/pVT can develop after pediatric resusci-
tation from an initial bradyasystolic arrest rhythm that 
is typically associated with hypoxic/asphyxial arrest in 
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children with preexisting shock or respiratory failure. In 
contrast, adult cardiac arrest with VF/pVT is often sud-
den, precipitated by acute coronary artery obstruction 
and myocardial ischemia.59
For this 2018 update, there were no additional pedi-
atric studies beyond the single study that formed the ba-
sis of the 2015 CoSTR. This study consists of data from 
an observational cohort of infants and children with 
IHCA from the Get With The Guidelines–Resuscitation 
registry.30 For this 2018 CoSTR, the Pediatric Task Force 
rereviewed this study by using the current ILCOR sys-
tematic review process and the 2018 PICO question to 
determine whether amiodarone or lidocaine, adminis-
tered in any setting (OHCA or IHCA) at any time during 
resuscitation or within 1 hour after ROSC, was associat-
ed with improvement in the critical outcomes of survival 
to hospital discharge with good neurological outcome 
or survival to hospital discharge or the important out-
come of ROSC or decreased rearrest after ROSC. The 
review identified no data on the use of antiarrhythmics 
to guide recommendations for pediatric OHCA.
For the critical outcome of survival to hospital dis-
charge, the task force analyzed the single observational 
cohort study with 302 patients.30 This cohort study 
was downgraded for lack of a control, indirectness 
(ie, patients were enrolled during an 8-year period of 
2000‒2008; in the years 2000‒2005, international 
recommendations for CPR and pediatric ALS differed 
substantially from current practice), risk of bias (ie, from 
a voluntary registry), and imprecision (ie, timing of drug 
administration and adverse events were not reported). 
This study found no difference in effect for lidocaine 
compared with amiodarone (25% versus 17%; P=NS; 
relative risk, 1.50; 95% CI, 0.90‒2.52); there were 
84 survivors per 1000 patients treated (range, <17 to 
>256, no statistically significant effect).30
For the important outcome of ROSC, in the same 
in-hospital observational study with 302 patients (qual-
ity downgraded as noted previously), ROSC was asso-
ciated with a higher percentage of the children who 
received lidocaine than those who received amiodarone 
(64% versus 44%; P=0.004; relative risk, 1.46; 95% 
CI, 1.13‒1.88), 202 more per 1000 treated (range, 
57‒386; number needed to treat, 5; 95% CI, 3‒18).30
Treatment Recommendations
We suggest that amiodarone or lidocaine be used in the 
treatment of pediatric shock-refractory VF/pVT (weak 
recommendation, very low-quality evidence).
Values and Preferences and Pediatric Task 
Force Insights
In making this recommendation, the task force consid-
ered the following.
We placed a higher value on the use of in-hospital 
pediatric registry data over extrapolation of data from 
studies of adult cardiac arrest. Although 3 adult RCTs 
compared lidocaine, amiodarone, and placebo, the 
populations studied are substantially different from both 
pediatric (prepubertal) and adolescent populations. The 
adult studies were heavily populated by subjects >50 
years of age and specifically excluded patients <18 years 
of age. In addition, the pediatric and adult studies do 
not consistently distinguish between primary and subse-
quent VF and their outcomes on the basis of drug thera-
pies. The distinction between initial and subsequent VF 
is an important one because pediatric survival from sub-
sequent VF is much lower than the survival from initial 
VF/pVT.28,30 Although the causes of IHCA and OHCA in 
children may differ, the task force feels that extrapolation 
of pediatric IHCA data to pediatric OHCA is reasonable.
The task force has low confidence in the quality of 
the data from the single study available for analysis.30 
This study included patients enrolled before the publi-
cation of the 2005 CoSTR and council guidelines. The 
2005 guidelines differed considerably from previous 
recommendations, with new emphasis on minimizing 
interruptions in chest compressions as part of overall 
high CPR quality to improve resuscitation outcomes.
The task force chose the critical and important out-
comes for this review on the basis of outcomes available 
in the literature and acceptable outcomes in the discipline. 
Longer-term outcomes, particularly functional outcomes, 
are more desirable but are not available at this time. Fur-
thermore, patient-centric outcomes may differ from those 
of the task force. Patients and families may place a higher 
value on short-term ROSC to give family members time 
to prepare for the child’s death or for organ donation. In 
addition, the patient and family may value survival, even 
with moderate neurological disability, over death.
Pediatric Task Force Knowledge Gaps
• Do antiarrhythmic drugs improve outcomes (includ-
ing patient- and family-centered outcomes) from 
pediatric OHCA or IHCA with VF/pVT? Do these 
drugs improve survival in specific populations of 
infants and children or under specific conditions?
• Does the timing of antiarrhythmic drug adminis-
tration with respect to defibrillation or epinephrine 
influence drug effectiveness?
• Is there a difference in antiarrhythmic effectiveness 
and adverse events based on the cause of the arrest 
(eg, channelopathy versus structural heart disease 
versus ischemia versus drug overdose) or for the 
treatment of initial versus subsequent VF/pVT?
• Does the use of antiarrhythmic drugs influence 
the cost-effectiveness, health equity, or resource 
requirements for infants and children who develop 
cardiac arrest with VF/pVT?
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